ACET
Adicet Bio Inc. Common StockHealth Care · ·
$7.93
▼ $1.23 (-13.4%)
Market Cap
$74.24M
Day Range
$7.42 - $8.88
52-Week Range
$6.01 - $17.44
Beta
—
Next Earnings
03.11.2026
ACET is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
🏢 Similar Stocks in the Same Sector
-18.3% (1Y)
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
🔍 Cross-Check
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟡 Mixed
✅ Why is the score relatively high?
- 🟢 Earnings per share (EPS) growth: 20.5%
- 🟢 Current ratio: 7.47
- 🟢 Price is above the 50-day average
- 🟢 Price is above the 200-day average
- 🟢 MACD histogram is positive — rising momentum
⚠️ What's concerning?
- 🔴 Estimated fair value: -$262.54 vs. price $7.93 (-3410.8%)
- 🔴 ATR: 5.8% of price
- 🔴 Return on equity (ROE): -73.4% (negative)
- 🔴 Free cash flow growth: -3.7%
- 🔴 Interest coverage: -3392.1x
🚦 Quality & Risk Checks
📰 News Trend
Based on real financial news (Finnhub)Everyone's writing about Adicet Bio Inc. Common Stock. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 2 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
📈 Technical Analysis
Based on the last 251 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 0 bearish · 3 neutral)
Conclusions
- 🟢Price vs. SMA 50 — Price is above the 50-day average
- 🟢Price vs. SMA 200 — Price is above the 200-day average
- 🟢MACD — MACD histogram is positive — rising momentum
- 🟢RSI — RSI 59.4 — healthy positive momentum
- 🟡Stochastic — %K 67.8 — neutral range
- 🟡ADX (trend strength) — ADX 17.0 — weak trend/choppy
- 🟢Relative strength vs. S&P 500 — +2.9% over the last 3 months relative to the index
- 🟢Bollinger Bands — Price is in the upper third of the Bollinger Bands (83%B) — strong momentum (risk of a pullback)
- 🟢ROC (rate of change) — ROC 12 days: 16.1%
- 🟢Parabolic SAR — Price is above the SAR point — uptrend
- 🟡CMF (money flow) — CMF 20 days: -0.05
Wyckoff Method Analysis
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
Evidence Behind This Read
- 🟢Rising price trend — A 10.0% change over the last 50 days, with no defined trading range.
- 🔴Divergence between price and cumulative money flow (A/D Line) — Price and the cumulative Accumulation/Distribution Line are moving in opposite directions — a classic Wyckoff sign that the move isn't backed by real money, and may be less stable than it looks.
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
🎯 Trade Planning (M.A.E.E Framework)
Based on a mechanical trading method: market structure → value zone → ATR-based exit point. Not investment advice — a calculation tool only.
1️⃣ Market Structure
🟢 Uptrend
The price is above the 200-day average — per the market-structure method, this environment mainly favors looking for buying (Long) opportunities.
2️⃣ Value Zone
🟡 Price far from value zone
The price is currently far from the 50-day average — the method recommends waiting for a "pullback" before entering, rather than chasing prices.
3️⃣ Suggested Exit Point (ATR-based)
Method formula: Stop-loss = support minusone ATR margin — this way the stop adapts to the stock's actual volatility, rather than an arbitrary number.
Entry
$9.16
Stop-Loss
$6.48
Risk per Share
$2.68
Direction
Long
Profit Targets by Risk/Reward Ratio (R)
1:2 R
$14.51
1:3 R
$17.19
1:5 R
$22.54
💰 Position Size Calculator
A core principle of the method: never risk a fixed dollar amount — risk a fixed percentage of equity, and let the position size vary according to the risk per share.
Suggested Position Size
37 sh.
💰 Financial Health
Profitability
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
Efficiency
ROE
-73.4%
ROA
-60.7%
ROIC
—
EPS
-$16.95
Balance Sheet
Cash
$38.92M
Total Debt
—
Current Ratio
7.47
Debt/Equity
—
Conclusions
- 🔴Return on equity (ROE) — Return on equity (ROE): -73.4% (negative)
- 🔴Return on assets (ROA) — Return on assets (ROA): -60.7% — weak
- 🟢Current ratio (liquidity) — Current ratio: 7.47
- 🔴Interest coverage — Interest coverage: -3392.1x
🚀 Growth
Revenue
אין נתונים היסטוריים זמינים.
Earnings per Share (EPS)
Net Income
Free Cash Flow (FCF)
Conclusions
- 🟢Earnings per share (EPS) growth — Earnings per share (EPS) growth: 20.5%
- 🔴Free cash flow growth — Free cash flow growth: -3.7%
- 🟡Net income growth — Net income growth: 0.3%
💎 Fair Value (Valuation)
Current Price
$7.93
Estimated Fair Value (DCF)
-$262.54
Gap
-3410.8%
🔴 Appears expensive relative to estimated value
Show all model (DCF) assumptions →
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-106.68M | $-97.87M |
| 2 | 8.1% | $-115.35M | $-97.09M |
| 3 | 6.3% | $-122.56M | $-94.64M |
| 4 | 4.4% | $-127.92M | $-90.62M |
| 5 | 2.5% | $-131.12M | $-85.22M |
Base FCF (last actual year)
$-96.98M
Terminal Value
$-2.07B
Present Value of Terminal Value
$-1.34B
Enterprise Value
$-1.81B
Net Debt
$0
Equity Value
$-1.81B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$23.10
Tangible Book Value per Share (Tangible NAV)
$23.10
Conclusions
- 🔴DCF Fair Value — Estimated fair value: -$262.54 vs. price $7.93 (-3410.8%)
- 🟢Tangible Net Asset Value (NAV) — NAV per share: $23.10
- 🟡P/E — P/E: -0.5
🕴️ Insider Trading
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 3 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| DUBIN STEVE | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Chodakewitz Jeffrey | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Grissinger Michael | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Sinclair Andrew | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Klickstein Lloyd | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Peng Katie | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Schor Chen | Grant/Award from Employer | 19.6.2026 | 55,000 | +55,000 | — |
| Aftab Blake | Grant/Award from Employer | 19.6.2026 | 55,000 | +55,000 | — |
| RA Capital Healthcare Fund LP | Other Transaction | 27.4.2026 | 932,624 | -250,000 | — |
| RA Capital Healthcare Fund LP | Other Transaction | 27.4.2026 | 1,402,833 | +250,000 | — |
| ORBIMED ADVISORS LLC | Open Market Sale | 8.4.2026 | 0 | -40,416 | $6.52 |
| ORBIMED ADVISORS LLC | Open Market Sale | 7.4.2026 | 34,923 | -29,319 | $6.53 |
| ORBIMED ADVISORS LLC | Open Market Sale | 7.4.2026 | 32,523 | -2,400 | $6.38 |
| Schor Chen | Grant/Award from Employer | 25.3.2026 | 468,555 | +468,555 | — |
| Harvey Brian Nicholas | Grant/Award from Employer | 25.3.2026 | 43,361 | +43,361 | — |
| Healey Don | Grant/Award from Employer | 25.3.2026 | 43,361 | +43,361 | — |
| Aftab Blake | Grant/Award from Employer | 25.3.2026 | 72,555 | +72,555 | — |
| Maltzman Julia D. | Grant/Award from Employer | 25.3.2026 | 72,555 | +72,555 | — |
| RA Capital Healthcare Fund LP | Open Market Purchase | 20.2.2026 | 1,182,624 | +74,751 | $7.27 |
| RA Capital Healthcare Fund LP | Open Market Purchase | 19.2.2026 | 1,107,873 | +74,268 | $7.21 |
| RA Capital Healthcare Fund LP | Open Market Purchase | 18.2.2026 | 1,033,605 | +74,577 | $7.04 |
| Schor Chen | Tax Withholding in Shares | 24.1.2026 | 6,820 | -1,755 | $8.44 |
| Harvey Brian Nicholas | Tax Withholding in Shares | 24.1.2026 | 5,145 | -546 | $8.44 |
| Healey Don | Tax Withholding in Shares | 24.1.2026 | 3,452 | -535 | $8.44 |
| Aftab Blake | Tax Withholding in Shares | 24.1.2026 | 2,981 | -535 | $8.44 |
📉 Short Interest
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
Monthly Trend — Open Short Interest
383,174 shares short as of 2026-07-15 · vs. 505,580 on 2026-06-30
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
Weekly Trend — Daily Short-Sale Activity
31.3% of trading volume this week was short selling, vs. 55.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
📰 News & Sentiment
Sentiment based on basic keywords (not AI) — 0 positive, 2 neutral, 0 negative out of the last 2 articles.
Benzinga · 6.8.2026
Benzinga · 5.8.2026